Growth Metrics

Opus Genetics (IRD) Debt Ratio (2019 - 2026)

Opus Genetics (IRD) reported Debt Ratio of 0.02 for Q1 2026, down 93.2% year-over-year from 0.26 in Q1 2025, and down 20.17% on a QoQ basis from 0.02 in Q4 2025.

Opus Genetics (IRD) has 5 years of Debt Ratio data on file, last reported at 0.02 in Q1 2026.

  • Quarterly Debt Ratio fell 93.2% year-over-year to 0.02 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.02 (down 93.2% YoY) and the FY2025 annual result came in at 0.02, changed N/A from the prior year.
  • Debt Ratio fell to 0.02 in Q1 2026 per IRD's latest filing, from 0.02 in the prior quarter.
  • Across five years, Debt Ratio topped out at 0.62 in Q3 2025 and bottomed at 0.0 in Q3 2023.
  • The 4-year median for Debt Ratio is 0.02 (2025), against an average of 0.18.
  • Peak annual rise in Debt Ratio reached 93.2% in 2026, while the deepest fall reached 93.2% in 2026.
  • Tracing IRD's Debt Ratio over 4 years: stood at 0.01 in 2022, then tumbled by 83.65% to 0.0 in 2023, then soared by 1209.37% to 0.02 in 2025, then decreased by 20.17% to 0.02 in 2026.
  • Per Business Quant, the three latest IRD Debt Ratio figures stand at 0.02 (Q1 2026), 0.02 (Q4 2025), and 0.62 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 0.18
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 1.41
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 0.05
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Opus Genetics 357.99 Mn 298.03 Mn - 0.02

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 0.02
Dec 31, 2025 0.02
Sep 30, 2025 0.62
Jun 30, 2025 0.33
Mar 31, 2025 0.26
Sep 30, 2023 0.00
Mar 31, 2022 0.01
Dec 31, 2019 1.52